Subscribe today to receive notice of our latest thought leadership, articles, and updates.
Insights
Recent updates
Sharing perspectives leads to greater understanding and fuels innovation
Check out our latest updates:
|
March 04, 2024 · Public Policy & Regulatory Affairs Team
The California Division of Workers’ Compensation (DWC) proposed significant rule changes in the final phase of integrating its workers’ comp pharmacy reimbursement process into the state’s Medicaid (“Medi-Cal”) pharmacy reimbursement structure. Read more... |
|
February 28, 2024 · Public Policy & Regulatory Affairs Team
California corrects drug formulary, Kentucky introduces several work comp bills, Wisconsin bill would establish a work comp medical fee schedule, New York enhances prior auth portal, several other states introduce work comp firefighter coverage and presumption bills, and New Mexico eyes study on treatment with mushrooms Read more... |
|
January 17, 2024 · Clinical Team
The U.S. Food and Drug Administration (FDA) reported that Dr. Reddy’s voluntarily recalled one lot of tizanidine 4 mg tablets at the consumer level as a precautionary measure. Tizanidine is a skeletal muscle relaxant commonly prescribed for the treatment of muscle spasticity. Read more... |
|
|
December 06, 2023 · Clinical Team
FDA warns that the antiseizure medications levetiracetam and clobazam may cause life-threatening adverse reaction. Read more... |
|
|
November 29, 2023 · Clinical Team
In January, Optum clinical programs will adopt revised morphine equivalent dose (MED) conversion factors for the opioid analgesics hydromorphone, methadone, and tramadol to correlate with CDC Guidelines. However, these modifications are predicted to have little effect on Optum risk identification and clinical review programs. Read more... |
|
|
November 17, 2023 · Clinical Team
Opvee® (nalmefene) nasal spray now available for emergency treatment of opioid overdoses, but currently non-formulary on all standard formularies until review by Optum P&T Committee. One unit of Opvee will likely be allotted per year by CMS. For WCMSAs, exposure for opioid antagonists like Opvee is unlikely to be significant. Read more... |
|
|
October 12, 2023 · Clinical Team
The 3Q 2023 Brand-Generic Pipeline update Read more... |
|
|
September 20, 2023 · Clinical Team
Zavzpret – indicated for the acute treatment of migraine with or without aura in adults – is now available as a 10 mg nasal spray device. Read more... |
|
|
September 15, 2023 · Clinical Team
According to the U.S. Food and Drug Administration (FDA), Duexis — a single-tablet combination product containing ibuprofen, a nonsteroidal anti‐inflammatory drug (NSAID), and famotidine, a histamine H2–receptor blocker — will no longer be manufactured. Read more... |
|
|
September 01, 2023 · Clinical Team
Earlier this year, the American Geriatrics Society (AGS) published an update to the AGS Beers Criteria® for potentially inappropriate medication (PIM) use in older adults (65 years of age and older). Older adults are more likely to experience unwanted adverse effects and be more sensitive to certain medications. Read more... |
|
|
August 16, 2023 · Public Policy & Regulatory Affairs Team
Brief postings include proposed updates to California DWC medical treatment guidelines and the Michigan Supreme Court rules on retro-applicability of certain auto no-fault fee schedule provisions. Read more... |
|
|
August 11, 2023 · Clinical Team
FDA approves additional over-the-counter naloxone products Read more... |
Page 3 of 5
